Poseida Therapeutics, Inc. (PSTX)의 가격은 얼마입니까?

Poseida Therapeutics, Inc. (PSTX)의 가격은 $9.50입니다.

Poseida Therapeutics, Inc. (PSTX)의 시가 총액은 무엇입니까?

Poseida Therapeutics, Inc. (PSTX)의 시가 총액은 $819.52M입니다.

Poseida Therapeutics, Inc. (PSTX) 배당금

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.

연도	배당금 (주식 분할 조정됨)	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

배당금 (주식 분할 조정됨)

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도	배당금	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

배당금

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	배당 지급 횟수	국가
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

회사

배당 지급 횟수

국가